Edwards Lifesciences Corporation (EW)
BMV
2,161.56
+632.31 (+41.35%)
Closed
Oct 8, 2026
Day's Range
2,149.252,164.22
52 wk Range
1,340.702,227.72
Financial Statements - EW - Edwards Lifesciences Corporation
Revenue
6.06B▼ 93.5%
Net Income
1.06B▼ 98.5%Net Margin 17.6%
EBITDA
1.96B▼ 93.5%
Free Cash Flow
1.33B▼ 70.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.06B | 93.90B | 6B | 5.38B | 5.23B | 4.38B |
| Cost of Goods | 1.33B | 19.29B | 1.37B | 1.08B | 1.24B | 1.08B |
| Gross Profit | 4.73B | 74.61B | 4.62B | 4.30B | 3.98B | 3.30B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.63B | 25.55B | 1.72B | 1.78B | 1.58B | 1.31B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -511.70M | -561.08M | -180.10M | -38.10M | 116.20M | -407.50M |
| Pre Tax Income | 1.27B | 26.72B | 1.59B | 1.76B | 1.70B | 916.70M |
| Income Tax | 216.90M | 2.62B | 198.70M | 245.50M | 198.90M | 93.30M |
| Net Income | 1.06B | 71.98B | 1.39B | 1.52B | 1.50B | 823.40M |
| EPS Basic | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 |
| EPS Diluted | 1.83 | 6.97 | 2.3 | 2.44 | 2.38 | 1.3 |
| Basic Shares Outstanding | 584.80M | 10.31B | 29.61M | 30.31M | 30.52M | 30.48M |
| Diluted Shares Outstanding | 584.80M | 10.31B | 29.61M | 30.31M | 30.52M | 30.48M |
| Ebit | 1.29B | 27.06B | 1.61B | 1.78B | 1.72B | 932.50M |
| Ebitda | 1.96B | 30.43B | 1.94B | 1.96B | 1.74B | 1.44B |
| Net Income Continuous Operations | 1.06B | 71.98B | 1.39B | 1.52B | 1.50B | 823.40M |
| Minority Interests | 4.10M | 4.90M | 3M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
